---
schema_version: "secwatch.filing_event.v1"
accession: "0001778922-26-000052"
form_type: "8-K"
ticker: "SGP"
cik: "0001778922"
company_name: "SpyGlass Pharma, Inc."
filed_at: "2026-10-19T20:10:28+00:00"
generated_at: "2026-10-19T20:11:04.157360+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SpyGlass reports 4-year BIM-IOL data: 37% IOP cut, 86% off drops, no product-related AEs

## Summary
- Interim 4-year data in 21 evaluable patients: mean IOP fell 37% to 15.9 mmHg from 25.1 mmHg post-washout across 75/150/300 mcg dose groups.
- 86% (18 of 21) remained off all topical IOP-lowering drops; 90% maintained ≥20/25 best corrected distance visual acuity.
- No product-related adverse events reported; FIH trial enrolled 23 patients, with 21 evaluable at 48 months (one moved abroad, one discontinued after cancer diagnosis).
- BIM-IOL System is designed to deliver bimatoprost for up to 7 years in the FIH trial; Phase 3 version targets 3 years, with a 505(b)(2) NDA planned.
- CEO Patrick Mooney cites approximately 1 million U.S. cataract procedures annually in glaucoma patients as the unmet need being targeted.

## SEC filing metadata
- accession: 0001778922-26-000052
- form_type: 8-K
- ticker: SGP
- cik: 0001778922
- company_name: SpyGlass Pharma, Inc.
- filed_at: 2026-10-19T20:10:28+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/0001778922-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/sgp-20261019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001778922-26-000052
- JSON: https://secwatch.observer/filing/0001778922-26-000052.json
- Plain text: https://secwatch.observer/filing/0001778922-26-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.